Citizens JMP’s $7 target on PRME

PRME Prime Medicine Inc

$3.21 → $7 (+118%) by Oct 2027

Market Outperform · reiterates · said Oct 6, 2026 · 12-month default horizon

Open: judged on the close on Oct 6, 2027

The article this target came from

Prime Medicine stock rating maintained at Market Outperform by Citizens

Investing.com · Oct 6, 2026

Investing.com - Citizens reiterated a Market Outperform rating on Prime Medicine shares (NASDAQ:PRME) and maintained a $7.00 price target.

Citizens JMP’s track record → Prime Medicine Inc →

A fact about what Citizens JMP published, as reported by Investing.com, not a recommendation from Dalsna Finance; Citizens JMP is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.